Module 3: Dermatotoxicity Studies: Why, When, and How to Conduct?
Recorded On: 04/10/2025
Part 1: In Vitro Assessments and Part 2: Dermal Product Development and Studies
This eLearning module will focus on the in vitro and in vivo studies needed to support first-in-human clinical trials for pharmaceutical products intended for topical application.
In vitro early safety screening tools are essential in the initial stages of dermal drug development for identifying potential local toxicities and adverse skin effects. This part of the module will identify available early screening tools that assist in the optimization of both the pharmaceutical and the delivery vehicle. The prominent tools discussed in this module are in vitro skin irritation assays, in vitro skin sensitization assays, and in vitro permeation testing (IVPT). In vitro skin irritation assays identify the potential of drug substances and final formulations to cause local irritation or damage to the skin. In vitro skin sensitization assays evaluate the potential of novel drug substances and formulations to cause allergic reactions on the skin. IVPT assesses the extent of permeation through the skin, allowing determination of local versus systemic exposure with related efficacy and toxicity implications and the influence of different formulations on delivery of the pharmaceutical. Collectively, these assays assist in selecting the optimum drug candidate and formulation for topical use while reducing animal use and the failure of the candidate later in development.
The module will also discuss the in vivo studies needed to determine both the local and systemic toxicity of dermal pharmaceutical products. These studies generally include the use of the rat as the rodent species and the minipig as the nonrodent species. As the set of in vivo nonclinical studies intended to support dermal administration are quite different from those intended for only systemic administration, these differences will be highlighted. In addition, the regulatory pathways for dermal products will be discussed to provide the differences between a novel dermal product and a previously approved systemic product that is being modified for use in a topical application. Together, this combination of in vitro and in vivo studies will provide a robust safety profile for regulatory agency review in supporting dermal drug development.
Vincent A. Murphy, PhD, DABT
Director of Toxicology
STILLMEADOW, Inc.
Dr. Vincent A. Murphy has over 30 years of experience as a toxicologist while working at Procter & Gamble, Array BioPharma, Inc., and STILLMEADOW, Inc., and as the sole proprietor of a consulting firm, Pharma Toxicology Advisors, LLC. In these positions, he contributed to all developmental phases of drug and other product development from discovery to marketing.
While at Procter & Gamble and Array BioPharma, Inc., he gained extensive experience in drug discovery and early-stage development of pharmaceuticals for oral, dermal, and injectable routes of administration. Dr. Murphy has designed and monitored studies internally and at contract laboratories that included dermal toxicity, irritation, and sensitization studies in animals and cumulative irritation and sensitization studies in humans. In vitro assays for drug candidate optimization were utilized by Dr. Murphy to assess eye and skin irritation, cytotoxicity, metabolism, genotoxicity, phototoxicity, enzyme induction, and safety pharmacology. He has used in silico programs, like Leadscope and Derek Nexus, for identification of potential toxicities of parent, metabolite, and impurities.
In his current position as Director of Toxicology at STILLMEADOW, Inc., he also serves as study director for dozens of acute dermal irritation and toxicity studies, local lymph node and Buehler skin sensitization studies, and occasional repeat-dose dermal toxicity studies. The use of in vitro and in silico assays is currently being explored.
Dr. Murphy earned a BS in Pharmacy from the University of Washington in Seattle and a PhD in Biochemical Pharmacology and Toxicology at the University of Utah in Salt Lake City. He has been a councilor, vice-president, and president of the In Vitro and Alternative Methods Specialty Section in the Society of Toxicology and has served the American College of Toxicology as a member of the Program and Communications Committees and Newsletter Subcommittee, and currently serves as a member of the Education Committee.
Jeffrey A. Klein, PhD, DABT
Advisor
SciLucent, Inc.
Dr. Jeff Klein is an Advisor in the Nonclinical Safety and Development group at SciLucent, Inc. In this role, he provides scientific and regulatory nonclinical consulting for drug development programs. He was previously a Senior Manager at Noven Pharmaceuticals leading nonclinical programs for transdermal drug development, Director of Preclinical Research at EP Technologies leading a team delivering large molecules through the skin using cold plasma, and Director of Toxicology and Dermatology at Sinclair Research, now Altasciences Preclinical Columbia. Dr. Klein is Past President of the Dermal Specialty Section of the Society of Toxicology and was certified by the American Board of Toxicology in 2012.